On the mechanism of action of antipsychotic drugs: A chemical reaction not receptor blockade

Current Drug Discovery Technologies

Volumn 10, Issue 3, 2013, Pages 195-208

  Miller, Christine L ^a  

^a MillerBio   (United States)

Author keywords

Catecholamines; Neuromelanin; Orthoquinones; Psychosis; Psychotic bipolar disorder; Schizophrenia

Indexed keywords

CHLORPROMAZINE; IODINE; MINOCYCLINE; OLANZAPINE; POLYMER;

ARTICLE; CHEMICAL REACTION; CONCENTRATION (PARAMETERS); DRUG EFFICACY; DRUG MECHANISM; ELECTROPHILICITY; HYDROPHOBICITY; IODINATION; ISOELECTRIC POINT; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; RECEPTOR BLOCKING;

ADRENOCHROME; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHLORPROMAZINE; HYDROGEN-ION CONCENTRATION; IODINE; MINOCYCLINE; POLYMERIZATION; SODIUM CHLORIDE; TEMPERATURE;

EID: 84879730353     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/1570163811310030003     Document Type: Article

References (112)

1. Nelson GN, Masuda M, Holmes TH. Correlation of behavior and catecholamine metabolite excretion. Psychosom Med 1966; 28: 1966216-26.
2. O'Keeffe R, Sharman DF, Vogt M. Effect of drugs used in psychoses on cerebral dopamine metabolism. Br J Pharmacol 1970; 38: 287-304.
3. Pollin W. A possible genetic factor related to psychosis. Am J Psychiatry 1971; 128: 311-7.
4. Lieberman JA, Koreen AR. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull 1993; 19: 371-429.
5. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987; 1: 133-52.
6. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251: 238-46.
7. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367-77.
8. Lidsky TI, Yablonsky-Alter E, Zuck LG, Banerjee SP. Antipsychotic drug effects on glutamatergic activity. Brain Res 1997; 764: 46-52.
9. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10: 79-104.
10. Freedman R, Adler LE, Bickford P, et al. Schizophrenia and nicotinic receptors. Harv Rev Psychiatry 1994; 2: 179-92.
11. Chew ML, Mulsant BH, Pollock BG, et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006; 88: 63-72.
12. Conley RR, Carpenter WT, Tamminga CA. Time to clozapine response in a standardized trial. Am J Psychiatry 1997; 154: 1243-7.
13. Rosenheck R, Evans D, Herz L, et al. How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. Schizophr Bull 1999; 25: 709-19.
14. Woerner MG, Robinson DG, Alvir JM, Sheitman BB, Lieberman JA, Kane JM. Clozapine as a first treatment for schizophrenia. Am J Psychiatry 2003; 160: 1514-6.
15. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 2006; 163: 743-5.
16. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164: 1050-60.
17. Glick ID, Bossie CA, Alphs L, Canuso CM. Onset and persistence of antipsychotic response in patients with schizophrenia. J Clin Psychopharmacol 2009; 29: 542-7.
18. Case M, Stauffer VL, Ascher-Svanum H, et al. The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychol Med 2010; 7: 1-10.
19. Ruberg SJ, Chen L, Stauffer V, et al. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 2011; 11: 23.
20. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003; 60: 1228-35.
21. Nordström AL, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) 1992; 106: 433-8.
22. Bench CJ, Lammertsma AA, Grasby PM, et al. The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psychopharmacology (Berl.) 1996; 124: 141-7.
23. Nyberg S, Farde L, Halldin C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997; 16: 1-7.
24. Takano A, Suhara T, Kusumi I, et al. Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 75-81.
25. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004; 63:423-32.
26. Kornhuber J, Wiltfang J, Riederer P, Bleich S. Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distribution. Eur Arch Psychiatry Clin Neurosci 2006; 256: 2742-80.
27. Freedman R, Olincy A, Ross RG, et al. The genetics of sensory gating deficits in schizophrenia. Curr Psychiatry Rep 2003; 5: 155-61.
28. Berry N, Jobanputra V, Pal H. Molecular genetics of schizophrenia: a critical review. J Psychiatry Neurosci 2003; 28: 415-29.
29. Hoogendoorn ML, Bakker SC, Schnack HG, et al. No association between 12 dopaminergic genes and schizophrenia in a large Dutch sample. Am J Med Genet B Neuropsychiatr Genet 2005; 134B: 6-9.
30. Allen N, Bagade S, McQueen MB, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. NatGenet 2008; 40: 827-34.
31. Levinson DF, Shi J, Wang K, et al. Genome-wide association study of multiplex schizophrenia pedigrees. Am J Psychiatry 2012; 169: 963-73.
32. Lisman JE, Coyle JT, Green RW, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008; 31: 234-42.
33. Miller CL, Murakami P, Ruczinski I, et al. Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder. Schizophr Res 2009; 113: 259-67.
34. Denovan-Wright EM, Devarajan S, Dursun SM, Robertson HA. Maintained improvement with minocycline of a patient with advanced Huntington's disease. J Psychopharmacol, 2002; 16: 393-4.
35. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 304-7.
36. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. J Clin Neuropharmacol 2008; 31: 287-92.
37. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71: 138-49.
38. Miyaoka T, Wake R, Furuya M, et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an openlabel study. Prog Neuropsychopharmacol Biol Psychiatry 2012; 37: 222-6.
39. Greiner AC, Nicolson GA, Baker RA. Therapy of chlorpromazine melanosis: A preliminary report. Can Med Assoc J 1964; 91: 636-8.
40. Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol 2001; 2: 253-62.
41. Buszman E, Betlej B, Wrzeniok D, Radwaska-Wala B. Effect of metal ions on melanin-local anaesthetic drug complexes. Bioinorg Chem Appl 2003; 1: 113-22.
42. Claffey DJ, Stout PR, Ruth JA. 3H-nicotine, 3H-flunitrazepam, and 3H-cocaine incorporation into melanin: a model for the examination of drug-melanin interactions. J Anal Toxicol 2001; 25: 607-11.
43. Schwarcz R, Rassoulpour A, Wu HQ, et al. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001; 50: 521-30.
44. Erhardt S, Blennow K, Nordin C, Skogh E, Lindström LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001; 313: 96-98.
45. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 2004; 15: 618-29.
46. Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006; 1073-1074: 25-37.
47. Miller CL, Llenos IC, Cwik M, Walkup J, Weis S. Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem Int 2008; 52: 1297-303.
48. Condray R, Dougherty GG, Keshavan MS, et al. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol 2011; 14: 756-67.
49. Myint AM, Schwarz MJ, Verkerk R, et al. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication- naïve and medication-free schizophrenic patients. Brain Behav Immun 2011; 25: 1576-81.
50. Linderholm KR, Skogh E, Olsson SK, et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 2012; 38: 426-32.
51. Severinsen JE, Als TD, Binderup H, et al. Association analyses suggest GPR24 as a shared susceptibility gene for bipolar affective disorder and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 524-33.
52. Abou Jamra R, Schulze TG, Becker T, et al. A systematic association mapping on chromosome 6q in bipolar affective disorder-evidence for the melanin-concentrating-hormone-receptor-2 gene as a risk factor for bipolar affective disorder. Am J Med Genet B. Neuropsychiatr Genet 2010; 153B: 878-84.
53. Demontis D, Nyegaard M, Christensen JH, et al. The gene encoding the melanin-concentrating hormone receptor 1 is associated with schizophrenia in a Danish case-control sample. Psychiatr Genet 2012; 22: 62-9.
54. Galzigna L. Interaction of chloropromazine with adrenochrome and interference of a possible endogenous psychotogenic agent with some synaptic enzyme activities. Biochem Pharmacol 1972; 21: 203-7.
55. Hoffer A, Osmond H, Smythies JR. Schizophrenia. A new approach. Part II. Ment Sci 1954; 100: 29-45.
56. Schwarz BE, Sem-Jacobsen C, Petersen MC. Effects of mescaline, LSD-25 and adrenochrome on depth electrograms in man. Arch Neurol Psychiat 1956; 75: 579-87.
57. Grof S. Clinical and experimental study of central effects of adrenochrome. J Neuropsychiat 1963; 5: 33-50.
58. LaBrosse EH, Axelrod J, Kpoin IJ, Kety SS. Metabolism of 7-H3-epinephrine-d-bitartrate in normal young men. J Clin Invest 1961; 40: 253-60.
59. Axelrod J. The metabolism storage and release of catecholamines. Recent Progr Hormone Res 1985; 21: 597-622.
60. Hegedus ZL, Altschule MD. Studies on aminochromes III. Transformation of 1-epinephrine, adrenochrome and adrenolutin into plasma-soluble melanins during incubation in human blood plasma. Arch Biochem Biophys 1968; 126: 388.
61. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978; 14: 633-43.
62. Guarnieri C, Ventura C. Inhibition by ceruloplasmin of the cardiac sarcolemmal adrenochrome formation. Biosci Rep 1985; 5: 473-6.
63. Kern C, Mautz DS, Bernards CM. Epinephrine is metabolized by the spinal meninges of monkeys and pigs. Anesthesiology 1995; 83: 1078-81.
64. Roberts A, Bar-Or D, Winkler JV, Rael LT. Copper-induced oxidation of epinephrine: protective effect of D-DAHK, a synthetic analogue of the high affinity copper binding site of human albumin. Biochem Biophys Res Commun 2003; 304: 755-7.
65. Remião F, Milhazes N, Borges F, et al. Synthesis and analysis of aminochromes by HPLC-photodiode array. Adrenochrome evaluation in rat blood. Biomed Chromatogr 2003; 17: 6-13.
66. Costa VM, Silva R, Ferreira LM, et al. Oxidation process of adrenaline in freshly isolated rat cardiomyocytes: formation of adrenochrome, quinoproteins, and GSH adduct. Chem Res Toxicol 2007; 20: 1183-91.
67. Yates JC, Taam GM, Singal PK, Beamish RE, Dhalla NS. Protection against adrenochrome-induced myocardial damage by various pharmacological interventions. Br J Exp Pathol 1980; 61: 242-55.
68. Tappia PS, Hata T, Hozaima L, Sandhu MS, Panagia V, Dhalla NS. Role of oxidative stress in catecholamine-induced changes in cardiac sarcolemmal Ca2+ transport. Arch Biochem Biophys 2001; 387: 85-92.
69. Tse DC, McCreery RL, Adams RN. Potential oxidative pathways of brain catecholamines. J Med Chem 1976; 19: 37-40.
70. Smythies J. The adrenochrome hypothesis of schizophrenia revisited. Neurotox Res 2002; 4: 147-50.
71. Green S, Mazur A, Shorr E. Mechanism of the catalytic oxidation of adrenaline by ferritin. J Biol Chem 1956; 220: 237-55.
72. Heacock RA, Mattok GL, Wilson DL. The stability of adrenochrome and its solutions. Can J Biochem Physiol 1963: 41: 1721-31.
73. Bowness JM, Mortone RA. The association of zinc and other metals with melanin and a melanin-protein complex. Biochem J 1953; 53: 620-6.
74. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005; 106: 1864-6.
75. Nosanchuk J D, Rosas AL, Lee SH, Casadeval A. Melanisation of Cryptococcus neoformans in infected human brain tissue. Lancet 2000; 355: 2049-50.
76. Panzella L, Manini P, Monfrecola G, d'Ischia M, Napolitano A. An easy-to-run method for routine analysis of eumelanin and pheomelanin in pigmented tissues. Pigment Cell Res 2007; 20: 128-33.
77. Greco G, Wakamatsu K, Panzella L, Ito S, Napolitano A, d'Ischia M. Isomeric cysteinyldopas provide a (photo)degradable bulk component and a robust structural element in red human hair pheomelanin. Pigm Cell Melanoma Res 2009; 22: 319-27.
78. Bhatnagar V, Anjaiah S, Puri N, Darshanam BN, Ramaiah A. pH of melanosomes of B 16 murine melanoma is acidic: its physiological importance in the regulation of melanin biosynthesis. Arch Biochem Biophys 1993; 307: 183-92.
79. Puri N, Gardner JM, Brilliant MH. Aberrant pH of melanosomes in pink-eyed dilution (p) mutant melanocytes. J Invest Dermatol 2000; 115: 607-13.
80. Schlereth DD, Karyakin AA. Electropolymerization of phenothiazine, phenoxazine and phenazine derivatives: characterization of the polymers by UV-visible difference spectroelectrochemistry and Fourier transform IR spectroscopy. J Electroanal Chem 1995; 395: 221-32.
81. Abu-Abdoun II, Ledwith A. A cationic polymerization photochemically and thermally induced by phenothiazine cation radical salts. Eur Polvm J 1997; 33: 1671-9.
82. Edenborough M. Organic Reaction Mechanisms: A Step by Step Approach. Taylor&Francis: London 1999.
83. Brown WH, Foote CS, Iverson BL, Anslyn EV. Organic Chemistry. Fifth ed., Brooks/Cole Cengage Learning: California 2011.
84. Nesvadba P. Radical polymerization in industry in: Encyclopedia of Radicals in Chemistry, Biology and Materials. John Wiley&Sons: New York 2012.
85. d'Ischia M, Napolitano A, Pezzella A, Meredith P, Sarna T.Chemical and structural diversity in eumelanins: unexplored biooptoelectronic materials. Angew Chem Int Ed Engl 2009; 48: 3914-21.
86. Land EJ, Ramsden CA, Riley PA. Quinone chemistry and melanogenesis. Methods Enzymol 2004; 378: 88-109.
87. Greco G, Panzella L, Gentile G, et al. A melanin-inspired prooxidant system for dopa(mine) polymerization: mimicking the natural casing process. Chem Commun (Camb) 2011; 47: 10308-10.
88. Cheng HY, Sackett PH, McCreery RL. Reactions of chloropromazine cation radical with physiologically occurring nucleophiles. J Med Chem 1978; 21: 948-52.
89. Clayden J, Greeves N, Warren S, Wothers P. Polymerization in: Organic Chemistry. First ed. USA: Oxford University Press 2000; pp 1451-80.
90. Taurog A, Howells EM. Enzymatic iodination of tyrosine and thyroglobulin with chloroperoxidase. J Biol Chem 1966; 241: 1329-39.
91. Thakuria R, Nangia A. Polymorphic form IV of olanzapine. Acta Crystallogr C 2011; 67: o461-463.
92. Kalyanaraman B, Sohnle PG. Generation of free radical intermediates from foreign compounds by neutrophil-derived oxidants. J Clin Invest 1985; 75: 1618-22.
93. Chakraborty AK, Platt JT, Kim KK, Kwon BS, Bennett DC, Pawelek JM. Polymerization of 5,6-dihydroxyindole-2-carboxylic acid to melanin by the pmel 17/silver locus protein. Eur J Biochem 1996; 236: 180-8.
94. Jhirwal OP, Parsad D, Basu D. Skin hyperpigmentation induced by olanzapine, a novel antipsychotic agent. Int J Dermatol 2004; 43: 778-9.
95. Scherzer T, Decker U. The effect of temperature on the kinetics of diacrylate photopolymerizations studied by Real-time FTIR spectroscopy. Polymer 2000; 41: 7681-90.
96. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 2006; 10: 515-31.
97. Peuskens J, Mertens C, Geerts S, Gillain B, Van Vleymen B. Open study evaluating the onset of antipsychotic action of olanzapine in the treatment of patients with schizophrenia, schizophreniform or schizo-affective disorder. Int J Psychiatry Clin Pract 2004; 8: 199-204.
98. Strassman RJ. Human Psychopharmacology of LSD, Dimethyltryptamine, and Related Compounds.in: Pletscher A, Ed. Fifty Years of LSD: Current Status and Perspectives of Hallucinogens (A Symposium of the Swiss Academy of Medical Sciences -Lugano-Agno 1993). England: The Parthenon Publishing Group 1994; pp. 145-174.
99. Moriyama Y, Tsai HL, Futai M. Energy-dependent accumulation of neuron blockers causes selective inhibition of neurotransmitter uptake by brain synaptic vesicles. Arch Biochem Biophys 1993; 305 278-81.
100. Zhang G, Terry AV, Bartlett MG. Sensitive liquid chromatography/tandem mass spectrometry method for the determination of the lipophilic antipsychotic drug chlorpromazine in rat plasma and brain tissue. J Chromatogr B Analyt. Technol Biomed Life Sci 2007; 854: 68-76.
101. Winek CL, Wahba WW, Winek CL, Balzer TW. Drug and chemical blood-level data 2001. Forensic Sci Int 2001; 122: 107-23.
102. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124: 57-73.
103. Aravagiri M, Teper Y, Marder SR. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 1999; 20: 369-77.
104. Pastuszko A, Wilson DF, Erecinska M. Energetics of gammaaminobutyrate transport in rat brain synaptosomes. J Biol Chem 1982; 257: 7514-9.
105. Rodgers AD, Curzon G. Melanin formation by human brain in vitro. J Neurochem 1975; 24: 1123-9.
106. Smythies J. On the function of neuromelanin. Proc Biol Sci 1996; 263: 487-9.
107. Pezzella A, Iadonisi A, Valerio S, et al. Disentangling eumelanin "black chromophore": visible absorption changes as signatures of oxidation state-and aggregation-dependent dynamic interactions in a model water-soluble 5,6-dihydroxyindole polymer. J Am Chem Soc 2009; 131(42): 15270-5.
108. Fornstedt B, Pileblad E, Carlsson A. In vivo autoxidation of dopamine in guinea pig striatum increases with age. J Neurochem 1990; 55: 655-9.
109. Zhang X, Monroe ME, Chen B, et al. Endogenous 3,4-dihydroxyphenylalanine and dopaquinone modifications on protein tyrosine: links to mitochondrially derived oxidative stress via hydroxyl radical. Mol Cell Proteomics 2010; 9: 1199-208.
110. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000; 6: 797-801.
111. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 2010; 112: 226-38.
112. Altschule MD, Hegedus ZL. The aminochromes and schizophrenia. J Orthomolecular Med 1972; 1: 8-17.